ReviewInternational journal of nanomedicine2026
Black Phosphorus Nanomaterials and the Senescent Osteoimmune Microenvironment: Mechanisms, Opportunities, Challenges, and Future Outlook.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The pathogenesis of senile osteoporosis involves immune cell imbalance, inflammaging, and dysregulation of the RANKL/OPG bone-immune axis, collectively defining the concept of immunoporosis. These interrelated processes mutually reinforce one another, leading to a 2-3-fold prolongation of bone healing time, while conventional single-target therapies fail to achieve coordinated regulation of bone regeneration and the immune microenvironment. Black phosphorus (BP) nanomaterials, as an emerging class of biomaterials, represent a paradigm shift from "passive scaffolds" to "active immuno-bone synergistic regulators." BP exerts multifunctional effects by restoring macrophage M1/M2 polarization balance, scavenging reactive oxygen species (ROS) to disrupt inflammatory feedback loops, and modulating the RANKL/OPG axis, thereby promoting a transition from a pro-inflammatory, destructive state to an anti-inflammatory, reparative phenotype. Experimental evidence indicates that BP can reduce pro-inflammatory cytokine expression by approximately 60% and achieve bone defect bridging rates of up to 93%. However, the clinical translation of BP remains challenged by the complexity of aging-related immune mechanisms, insufficient long-term safety data, and unclear translational pathways. This Perspective systematically discusses the regulatory mechanisms of BP in the aged osteoimmune microenvironment, the current limitations, and future research directions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.